Jan 11 |
Aclaris draws second downgrade despite Phase 2 win for eczema therapy
|
Jan 10 |
Aclaris downgraded at Jefferies despite mid-stage win for eczema therapy
|
Jan 10 |
Dow Surges 100 Points; PriceSmart Earnings Top Views
|
Jan 10 |
Aclaris posts topline data from mid-stage trial for eczema therapy
|
Jan 10 |
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
|
Jan 4 |
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
|
Dec 19 |
Aclaris to slash 46% of workforce as it reprioritizes drug programs
|
Dec 19 |
Aclaris Therapeutics Provides Corporate Update
|
Dec 5 |
Aclaris Therapeutics announces patent license agreement with Sun Pharma for alopecia
|
Dec 5 |
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
|